| Biological Sciences | 2021-2025 | 194 | CN 82 | 99.81 |
| Medical and Health Sciences | 2021-2025 | 847 | CN 81 | 99.80 |
| Cancer Research | Lifetime | 322 | CN 23 | 98.09 |
| Biochemistry | Lifetime | 369 | CN 30 | 94.77 |
| Molecular Biology | 2021-2025 | 110 | CN 51 | 99.57 |
| Cancer Research | 2021-2025 | 27 | CN 12 | 98.99 |
| Cardiology and Cardiovascular Medicine | 2021-2025 | 223 | CN 1 | 98.29 |
| Pulmonary and Respiratory Medicine | 2021-2025 | 300 | CN 43 | 97.22 |
| Epidemiology | 2021-2025 | 529 | CN 58 | 95.20 |
| Oncology | 2021-2025 | 673 | CN 73 | 89.84 |
| Biochemistry | 2021-2025 | 77 | CN 20 | 85.36 |
| Infectious Diseases | 2021-2025 | 996 | CN 92 | 67.23 |
| Cancer-related molecular mechanisms research | Lifetime | 186 | CN 79 | 99.23 |
| MicroRNA in disease regulation | Lifetime | 157 | CN 51 | 99.28 |
| Circular RNAs in diseases | Lifetime | 85 | CN 44 | 99.22 |
| Extracellular vesicles in disease | Lifetime | 130 | CN 29 | 98.55 |
| COVID-19 Clinical Research Studies | Lifetime | 511 | CN 78 | 98.03 |
| Ferroptosis and cancer prognosis | Lifetime | 215 | CN 95 | 97.29 |
| Long-Term Effects of COVID-19 | Lifetime | 447 | CN 31 | 96.60 |
| Cancer, Hypoxia, and Metabolism | Lifetime | 886 | CN 51 | 97.93 |
| Eicosanoids and Hypertension Pharmacology | Lifetime | 330 | CN 10 | 97.83 |
| Autophagy in Disease and Therapy | Lifetime | 978 | CN 203 | 94.78 |
| Cardiac Fibrosis and Remodeling | Lifetime | 560 | CN 50 | 93.31 |
| Signaling Pathways in Disease | Lifetime | 968 | CN 58 | 92.12 |
| Cancer-related molecular mechanisms research | 2021-2025 | 67 | CN 44 | 99.29 |
| MicroRNA in disease regulation | 2021-2025 | 63 | CN 39 | 98.93 |
| Extracellular vesicles in disease | 2021-2025 | 50 | CN 34 | 98.61 |
| RNA modifications and cancer | 2021-2025 | 176 | CN 119 | 98.25 |
| Viral Infections and Immunology Research | 2021-2025 | 48 | CN 11 | 96.79 |
| Cardiac Fibrosis and Remodeling | 2021-2025 | 19 | CN 5 | 96.49 |
| Signaling Pathways in Disease | 2021-2025 | 10 | CN 3 | 94.28 |
| Ferroptosis and cancer prognosis | 2021-2025 | 143 | CN 113 | 97.55 |
| Cardiovascular Function and Risk Factors | 2021-2025 | 461 | CN 19 | 96.92 |
| Eicosanoids and Hypertension Pharmacology | 2021-2025 | 32 | CN 5 | 92.90 |
| Circular RNAs in diseases | 2021-2025 | 235 | CN 170 | 94.88 |
| Autophagy in Disease and Therapy | 2021-2025 | 315 | CN 155 | 91.09 |
| Hormonal Regulation and Hypertension | 2021-2025 | 281 | CN 23 | 90.68 |
| Cancer, Lipids, and Metabolism | 2021-2025 | 526 | CN 197 | 88.76 |
| RNA Research and Splicing | 2021-2025 | 903 | CN 262 | 87.35 |
| Cancer, Hypoxia, and Metabolism | 2021-2025 | 939 | CN 419 | 86.41 |
| Heart Failure Treatment and Management | 2021-2025 | 998 | CN 32 | 89.11 |
| Cancer Mechanisms and Therapy | 2021-2025 | 354 | CN 139 | 84.39 |
| Chemotherapy-induced cardiotoxicity and mitigation | 2021-2025 | 303 | CN 23 | 83.92 |
| RNA regulation and disease | 2021-2025 | 390 | CN 94 | 80.70 |
| S100 Proteins and Annexins | 2021-2025 | 573 | CN 108 | 68.52 |
| Advanced Glycation End Products research | 2021-2025 | 922 | CN 355 | 58.54 |
| Bioactive Natural Diterpenoids Research | 2021-2025 | 465 | CN 308 | 40.51 |
